Description

Technical Parameters

Introduction

peptides

product-1400-1400

Products Description

### Systematic introduction of Cagrilintide peptide

Cagrilintide is a new long-acting amylin analog developed by Novo Nordisk, mainly used for the treatment of obesity. Its design combines structural modification technology and pharmacodynamic optimization strategy, aiming to prolong half-life and enhance targeting. The following systematic classification and analysis of its characteristics from the perspectives of structure, physicochemical properties, formulation type and stability.

---

### **1. Structural classification and functional advantages**

#### **1. Acylated modified peptide**

- **Structural characteristics**: The main chain of Cagrilintide introduces fatty acid side chains (such as C18 diacid) through acylation reaction, and the binding site is often located at lysine residues, forming a self-assembled structure to delay release.

- **Advantages**:

- **Long-term**: The fatty acid side chain binds to albumin, significantly prolonging the half-life to more than 7 days, supporting once-weekly dosing.

- **Enhanced targeting**: The modified spatial conformation optimizes receptor binding and improves the efficiency of amylin receptor activation.

- **Physical and chemical properties**:

- **Molecular weight**: about 4,110 Da (including modified groups).

- **Solubility**: easily soluble in water at neutral pH, isoelectric point (pI) about 5.8, may form colloids under acidic conditions.

- **Color characteristics**: pure product is white crystalline powder, lyophilized preparation is loose white solid.

#### **2. Disulfide bond stabilized structure**

- **Structural characteristics**: retain the core sequence of natural amylin (including 2 disulfide bonds), maintain α-helical conformation, and enhance resistance to enzymatic hydrolysis.

- **Advantages**:

- **Improved stability**: disulfide bonds reduce pepsin cleavage and improve oral bioavailability (although injection is still the main method at present).

- **Reduced immunogenicity**: the structure is close to endogenous hormones, reducing the risk of antibody formation.

- **Physical and chemical properties**:

- **Thermal stability**: no obvious degradation below 80°C, better than unmodified peptides.

- **Photosensitivity**: It needs to be stored away from light, and ultraviolet radiation can easily cause disulfide bonds to break.

---

### **2. Preparation type and physical properties**

#### **1. Lyophilized powder injection**

- **Preparation process**: Freeze-drying technology is used, and mannitol or sucrose is added as an excipient.

- **Physical and chemical parameters**:

- **Appearance**: White or off-white porous blocks, colorless and transparent solution after reconstitution.

- **pH range**: 7.0-7.5, phosphate or histidine is commonly used as the buffer system.

- **Advantages**: Good long-term stability (up to 24 months at 2-8℃), easy to transport.

#### **2. Prefilled injection**

- **Formulation characteristics**: Liquid preparations contain preservatives (such as phenol) and isotonic regulators (sodium chloride).

- **Physical performance**:

- **Color**: Colorless to light yellow, related to concentration (high concentration may show opalescence due to the Tyndall effect).

- **Viscosity**: Low viscosity (<10 cP), suitable for subcutaneous injection.

- **Advantages**: Ready to use, easy to use, high patient compliance.

---

### **3. Stability classification and storage conditions**

#### **1. Thermal stability**

- **Accelerated test data**: Under 40℃/75% RH conditions, the degradation rate is <5% in 6 months, and the main degradation pathway is deamidation.

- **Storage recommendations**: Long-term storage requires refrigeration at 2-8℃, and avoid repeated freezing and thawing.

#### **2. Light stability**

- **Photolysis mechanism**: Ultraviolet light (above 290 nm) triggers tryptophan oxidation, resulting in loss of activity.

- **Packaging strategy**: Brown glass bottles or aluminum foil bags are kept away from light, and the light intensity must be <2000 lux.

#### **3. pH-dependent stability**

- **Optimum pH range**: 6.5-7.5, aggregation is likely to occur beyond this range (flocculation is visible to the naked eye).

- **Buffer optimization**: Histidine buffer is more effective than phosphate in inhibiting degradation under acidic conditions.

---

### **4. In-depth analysis of peptide color changes**

#### **1. Synthesis intermediate color**

- **Solid phase synthesis stage**: Resin-bound peptides are often light yellow (Fmoc protective group remains), and turn white after purification.

- **Impairment influence**: Oxidation byproducts (such as methionine sulfoxide) may cause slight yellowing, and HPLC purity>99% is required.

#### **2. Color changes in preparations**

- **Maillard reaction**: During high temperature sterilization, carbohydrate excipients combine with peptide amino groups to produce light brown (rare, strict process control is required).

- **Metal ion catalysis**: Iron or copper ion contamination triggers oxidation, which can be effectively inhibited by adding EDTA.

---

### **5. Clinical advantages and market positioning**

- **Combination therapy breakthrough**: Combined with semaglutide (GLP-1 analog), it synergistically regulates appetite and energy metabolism. Clinical trials show that the weight loss effect is improved by more than 30%.

- **Patient tolerance**: The incidence of gastrointestinal side effects is lower than that of single GLP-1 agonists (nausea incidence <15%).

- **Economic analysis**: Although the production cost is high (about $5,000 per gram), the weekly formulation design reduces overall medical expenses.

---

### **6. Future development direction**

- **Oral dosage form development**: Use SNAC carrier or nanoparticle encapsulation technology to improve gastrointestinal permeability.

- **Dual target design**: Fusion of GLP-1/amylin dual agonist structure to further simplify the treatment plan.

---

### **Conclusion**

Cagrilintide achieves a balance between efficacy and stability through innovative structural modification and formulation optimization. Its classification system covers molecular design, formulation science and stability management, providing a new paradigm for obesity treatment. With the breakthrough of delivery technology in the future, its application prospects will be broader.